IN BRIEF: AstraZeneca prices EUR1.4 billion in bonds at 3.1% and 3.3%

AstraZeneca PLC - Cambridge, England-based biopharmaceutical maker - Prices two tranches of ...

Alliance News 30 July, 2024 | 2:59PM
Email Form Facebook Twitter LinkedIn RSS

AstraZeneca PLC - Cambridge, England-based biopharmaceutical maker - Prices two tranches of eurobonds, raising a total of EUR1.40 billion for "general corporate purposes". Issues EUR650 million in fixed-rate notes with a coupon of 3.121% maturing in August 2030, and EUR750 million in fixed-rate notes with a coupon of 3.278% maturing in August 2033. The offering, by subsidiary AstraZeneca Finance LLC, is run by BNP Paribas, Goldman Sachs International, Morgan Stanley and Societe Genarale as joint book-running managers.

Current stock price: 12,259.34 pence, down 0.9% in London on Tuesday

12-month change: up 9.6%

By Tom Waite, Alliance News editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 12,274.44 GBX -0.72
BNP Paribas Act. Cat.A 64.24 EUR 0.66
Societe Generale SA 23.90 EUR 0.93
Morgan Stanley 103.42 USD 0.92
The Goldman Sachs Group Inc 506.93 USD 2.88

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures